ArticleViruses2022
Emerging Genotype IV Japanese Encephalitis Virus Outbreak in New South Wales, Australia.
Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Detection of Japanese encephalitis virus inParasite epidemiology and control · 2026Article
- Community Perspectives on Japanese Encephalitis Risk and Prevention in an Endemic Region of Australia.The Australian journal of rural health · 2026Article
- Knowledge, attitudes, and practices of local land services staff regarding Japanese encephalitis virus: A one health perspective.One health (Amsterdam, Netherlands) · 2026Article
- Seroprevalence of Japanese Encephalitis Virus, and Immunogenicity of the Vero-Cell Culture-Derived Vaccine in Hematopoietic Stem Cell Transplantation Recipients.Journal of Korean medical science · 2026Article
- mRNA Vaccine Against Japanese Encephalitis Virus Genotype IV Protects Against Lethal Infection.Viruses · 2026Article
- Article
- The hidden threats posed by Japanese encephalitis virus genotype V.Journal of virology · 2025Review
- Brain biopsy and metagenomic sequencing enhance aetiological diagnosis of encephalitis.Brain communications · 2025Article
- Characterization of genotype V Japanese encephalitis virus isolates from Republic of Korea.Emerging microbes & infections · 2024Article
- Japanese encephlu emergence in Australia: the potential population at risk.Annals of medicine and surgery (2012) · 2024Review
- Article
- Endogenous ZAP affects Zika virus RNA interactome.RNA biology · 2024Article
- Article
- Arthropod-Borne Flaviviruses in Pregnancy.Microorganisms · 2023Review
- Article
- The reemerging and outbreak of genotypes 4 and 5 of Japanese encephalitis virus.Frontiers in cellular and infection microbiology · 2023Review
- Clinical application value of metagenomic next-generation sequencing in the diagnosis of central nervous system infections.Frontiers in bioengineering and biotechnology · 2023Article
- Japanese Encephalitis Virus: The Emergence of Genotype IV in Australia and Its Potential Endemicity.Viruses · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The detection of a new and unexpected Japanese encephalitis virus (JEV) outbreak in March 2022 in Australia, where JEV is not endemic, demanded the rapid development of a robust diagnostic framework to facilitate the testing of suspected patients across the state of New South Wales (NSW). This nascent but comprehensive JEV diagnostic service encompassed serological, molecular and metagenomics testing within a centralised reference laboratory. Over the first three months of the outbreak (4 March 2022 to 31 May 2022), 1,061 prospective samples were received from 878 NSW residents for JEV testing. Twelve confirmed cases of Japanese encephalitis (JE) were identified, including ten cases diagnosed by serology alone, one case by metagenomic next generation sequencing and real-time polymerase chain reaction (RT-PCR) of brain tissue and serology, and one case by RT-PCR of cerebrospinal fluid, providing an incidence of JE over this period of 0.15/100,000 persons in NSW. As encephalitis manifests in <1% of cases of JEV infection, the population-wide prevalence of JEV infection is likely to be substantially higher. Close collaboration with referring laboratories and clinicians was pivotal to establishing successful JEV case ascertainment for this new outbreak. Sustained and coordinated animal, human and environmental surveillance within a OneHealth framework is critical to monitor the evolution of the current outbreak, understand its origins and optimise preparedness for future JEV and arbovirus outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.